WebImmune Therapeutics and Cytocom are planning to work with federal agencies to seek fast-track approval using Lodonal™ as a way to prevent or treat COVID-19 in high-risk groups who are infected with 2024-nCoV at clinical research centers across the country. IMUN is currently designing studies using Lodonal™ and IRT-101 as a monotherapy or in ... WebApr 7, 2024 · Contact Data CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For ...
Cytocom, Inc. Announces Agreement to Reacquire Rights to
WebMar 29, 2024 · About CytomX Therapeutics, Inc. 151 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO, California, 94080, United States +1 650 515 … WebApr 20, 2024 · Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform... university of pittsburgh implant center
Cytocom Inc. Announces Completed Merger with …
WebMar 6, 2024 · Using opioid treatments to manage immunity Cytocom’s main drug of focus is naltrexone, which is currently approved for use in treating alcoholism and opioid addiction. It’s a similar compound to... WebAug 20, 2024 · Cytocom has agreed to reacquire the emerging market rights for its late-stage drug candidates CYTO-201 and CYTO-401 from Immune Therapeutics in … WebPrincipal Scientist, Computational Biology at Beam Therapeutics Ashburn, Virginia, United States. 437 followers 445 connections. Join to view profile Report this profile ... university of pittsburgh information science